A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
NCT ID: NCT00081484
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
336 participants
INTERVENTIONAL
2004-06-30
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
methoxy polyethylene glycol-epoetin beta [Mircera]
30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
2
epoetin alfa or beta
iv or sc, as prescribed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
epoetin alfa or beta
iv or sc, as prescribed
methoxy polyethylene glycol-epoetin beta [Mircera]
30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* chronic renal anemia;
* on dialysis therapy for at least 12 weeks before screening;
* receiving iv or sc epoetin for at least 8 weeks before screening.
Exclusion Criteria
* administration of another investigational drug within 4 weeks before screening, or during the study period.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Covina, California, United States
Los Alamitos, California, United States
Los Angeles, California, United States
San Diego, California, United States
San Diego, California, United States
Tampa, Florida, United States
Honolulu, Hawaii, United States
South Holland, Illinois, United States
Baton Rouge, Louisiana, United States
Shreveport, Louisiana, United States
Shreveport, Louisiana, United States
Boston, Massachusetts, United States
Kalamazoo, Michigan, United States
Columbus, Mississippi, United States
Tupelo, Mississippi, United States
St Louis, Missouri, United States
Hackensack, New Jersey, United States
Flushing, New York, United States
New York, New York, United States
Orchard Park, New York, United States
Cleveland, Ohio, United States
Cleveland, Ohio, United States
Oregon City, Oregon, United States
Erie, Pennsylvania, United States
Lewistown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Columbia, South Carolina, United States
Charlottesville, Virginia, United States
Norfolk, Virginia, United States
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Greenfield Park, Quebec, Canada
Montreal, Quebec, Canada
Aix-en-Provence, , France
Chambéry, , France
Hyères, , France
Le Kremlin-Bicêtre, , France
Nantes, , France
Paris, , France
Rouen, , France
Erlangen, , Germany
München, , Germany
Nuremberg, , Germany
Como, , Italy
Modena, , Italy
Pavia, , Italy
Rzeszów, , Poland
Warsaw, , Poland
Carnaxide, , Portugal
Porto, , Portugal
Setúbal, , Portugal
Ponce, , Puerto Rico
San Juan, , Puerto Rico
Alicante, , Spain
Madrid, , Spain
Kaohsiung City, , Taiwan
Taichung, , Taiwan
Taipei, , Taiwan
Bangkok, , Thailand
Glasgow, , United Kingdom
Hertford, , United Kingdom
London, , United Kingdom
Salford, , United Kingdom
Swansea, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chung EY, Palmer SC, Saglimbene VM, Craig JC, Tonelli M, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2023 Feb 13;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BA17284
Identifier Type: -
Identifier Source: org_study_id